GH Research PLC
GHRS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001855129
No open-market purchases or sales by GH Research PLC insiders were filed in the last 90 days; 63 institutions reported holding it in 13F filings for Q2 2026, worth $1.38B in total; no superinvestor holds it.
Q3 2023 vs. Q2 2023
How the institutions holding GH Research PLC changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 34 | 29 | −5 |
| Shares | 29.6M | 29.0M | −630.0K (−2.1%) |
| Value | $351.6M | $291.5M | −$60.1M (−17.1%) |
New holders (1)
Institutions that held GH Research PLC at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Qube Research & Technologies Ltd | 109 | $1.09K | 0.00% |
Sold out (6)
Institutions that held GH Research PLC at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| OrbiMed Advisors LLC | 736,315 | $8.74M |
| Acuta Capital Partners, LLC | 244,828 | $2.90M |
| Pura Vida Investments, LLC | 25,000 | $296.6K |
| Corton Capital Inc. | 12,135 | $144.0K |
| Bank of Montreal | 10,641 | $133.3K |
| Tower Research Capital LLC (TRC) | 61 | $724 |